Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Blueprint Medicines

Request full access

Developing a new generation of highly selective and potent kinase therapies to dramatically improve the lives of patients with genomically defined diseases

Cambridge, United StatesFounded 2011Biotech & Life Sciences

At a glance

Status
Listed
Listing
IPO 2015

Blueprint Medicines in the Cambridge ecosystem

Live from Dealroom

The Blueprint Medicines office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

7 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A3 investors entered at this stage

Series B and later4 investors entered at this stage

Employees mapped 712 incl. 5 AI specialists
Founders Hidden — book a demo/100 quality score
Key operators 8 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia 7 alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Patents

Estimated portfolio value
$90M

80 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

See Blueprint Medicines on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.